Financial Data and Key Metrics Changes - KORU Medical Systems achieved revenue of over $10 million for the second consecutive quarter, representing a 27% year-over-year growth, driven by a 30% increase in the core subcutaneous immunoglobulin (SCIG) business [4][16] - Gross profit grew by 21% year-over-year, with a gross margin of 60.2%, a decrease of 320 basis points from the prior year due to higher manufacturing costs and geographical customer mix [5][18] - The company raised its full-year revenue guidance to $40.5-$41 million, indicating a growth of approximately 20%-22% [5][21] Business Line Data and Key Metrics Changes - The SCIG business grew by 30%, supported by international expansion and strong patient growth, while the U.S. SCIG business represented the largest recurring revenue base [4][6] - International revenue grew by 230%, with the company increasing its international market share from approximately 10% to 15%-20% in the underlying $60 million OUS SCIG market [16][8] - The company has nine active collaborations with potential new drugs expected to be added to its system by the end of 2026, with a commercial potential of up to $10 million by the end of 2028 [11][12] Market Data and Key Metrics Changes - The SCIG market is projected to grow approximately 9% annually over the next five years, outpacing the IVIG segment, with significant headroom for expansion due to increasing diagnoses of secondary immunodeficiency [6][7] - The oncology infusion consumables market is projected to grow from approximately $60 million in 2025 to $138 million by 2030, indicating a significant opportunity for KORU [15] Company Strategy and Development Direction - KORU is focused on expanding its pipeline and broadening its label through new collaborations, including two new PFT collaborations announced during the quarter [5][10] - The company aims to penetrate oncology infusion centers, with a successful U.S.-based oncology study validating its value proposition in this market [5][14] - KORU's strategy includes partnering with pharmaceutical companies to accelerate adoption and growth in the subcutaneous market [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum, highlighting robust growth in both U.S. and international markets, and reaffirmed guidance for gross margins and cash flow from operations [5][22] - The company anticipates continued growth driven by international opportunities and a strong SCIG market, with expectations to end the year with at least $8.2 million in cash [21][22] Other Important Information - The company reported a positive adjusted EBITDA and generated positive cash flow, reflecting disciplined operating expense management [5][19] - KORU's cash usage has decreased to $1.1 million year-to-date, representing a 60% decrease from the previous year [20] Q&A Session Summary Question: Feedback on oncology pilot study and reimbursement model - Management reported high satisfaction rates among nurses and patients, with 70% of nurses able to multitask during administration, and confirmed that existing reimbursement codes cover the administration of drugs using a pump [26][28] Question: Guidance for Q4 and 2026 outlook - Management indicated a strong acceleration in revenues expected for the second half of the year, with a split of approximately 70% U.S. business and 23-24% international business for Q4 [29][30] - For 2026, management is optimistic about growth opportunities, indicating a number starting with a two for revenue guidance [31] Question: Opportunities in the EU and market dynamics - Management highlighted significant growth potential in the EU driven by prefilled conversions, estimating a $10 million-$20 million opportunity overall [32][33] Question: Gross margin expectations - Management aims to maintain gross margins in the range of 61-63% while working towards a long-term goal of 65% [36][37] Question: Japan market entry and growth cadence - Management reported initial sales in Japan and indicated that while it remains a growth driver, the broader prefill opportunity is prioritized [39][43]

Core Viewpoint - The concept of "悟道" (enlightenment) in investing emphasizes understanding market dynamics and developing a personal strategy rather than relying on external opinions or luck [3][9]. Group 1: Understanding "悟道" - "悟道" is a process of continuous learning and self-discovery in investing, where one develops a unique perspective and method for profit [3][5][9]. - Achieving "悟道" means recognizing the essence of a market and knowing how to capitalize on it consistently, leading to stable profits rather than erratic gains [9][14]. - The journey of "悟道" involves adapting to changing market conditions and maintaining a calm mindset regardless of market fluctuations [2][8][14]. Group 2: Market Behavior and Personal Growth - Investors often feel enlightened during bull markets but realize their lack of true understanding when faced with bear markets [3][6]. - The ability to remain detached from emotional responses to market movements is a sign of having achieved "悟道" [1][4]. - Continuous improvement and learning from both successes and failures are crucial for developing a robust investment strategy [7][14]. Group 3: Practical Insights - Successful investors often focus on long-term strategies rather than short-term gains, which aligns with the principles of "悟道" [2][8]. - The importance of self-reflection and understanding one's own investment philosophy is highlighted as a key aspect of achieving "悟道" [4][13]. - Recognizing the limitations of one's knowledge and being selective about investment opportunities is part of the "悟道" process [9][12].

Group 1 - Han Chaodong and Liang Rui'an are prominent figures in the futures investment sector, with extensive experience and notable achievements in their respective fields [1][3][4] - Han Chaodong, chairman of Beijing Ruigu Investment Co., has dedicated over 32,000 hours to in-depth fundamental research in futures, excelling in both agricultural and industrial commodities [3] - Liang Rui'an, general manager of Shanghai Dazhun Asset Management Center, is recognized for his innovative application of supply and demand theory in value investing, achieving consistent profitability [4] Group 2 - The concept of "knowing and doing" in futures trading emphasizes that understanding the profit model is crucial for successful execution, challenging the notion that action is inherently difficult [5] - Investors should reflect on missed opportunities and ensure their research and operational capabilities align, particularly during significant market events [6] - Successful futures traders excel not only in analysis but also in leveraging their positions effectively, knowing when to increase or decrease their holdings [7] Group 3 - Continuous profitability in futures trading is viewed as a means of preparation for larger opportunities rather than merely accumulating small wins [8] - The ability to capitalize on major market movements is essential, requiring traders to maintain a flexible approach and adapt to changing market conditions [9][10] - Understanding the dynamics of arbitrage, particularly between different products and time periods, is critical for effective trading strategies [8] Group 4 - As fund sizes increase, the rate of return often diminishes due to liquidity constraints, suggesting that optimal fund sizes for higher returns should be kept at a manageable level [7][9] - Identifying significant market trends driven by supply and demand imbalances is crucial for successful trading, as balanced markets often yield less profitable opportunities [10][11] Group 5 - A trader's mindset is a vital component of success, with a good attitude being necessary for reaching top-tier performance in the futures market [12] - The relationship between traders and fund managers is likened to that of passengers and drivers, emphasizing the importance of risk management and adherence to rules [30]